louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04490837: Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID)
Official title: Rapid Diagnostic Test for COVID-19 Based on Antibody Detection
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid-19
Keywords: Antibodies
Covid-19
Rapid test
RBD
Lead sponsor: Corporacion Parc Tauli
Sponsor class: OTHER
First posted: 2020-07-29
Enrollment: 3500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with COVID-19 infection Professionals of an University Hospital

Brief summary: Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices. This test will be developed using innovative technology developed at the Parc Taulí University Hospital, which increases the immunogenicity of SARS-CoV-2 differential antigens. The increased immunogenicity of these antigens will allow to detect, with a high sensitivity and specificity, the antibodies in the serum of patients infected with SARS-CoV-2. This test will serve to confirm dubious results as well as reduce false negatives from the PCR test, which will ultimately help reduce transmission of the infection.


Eligibility criteria: Inclusion Criteria:

* Professional from Parc Taulí University Hospital
* Patients with clinical, radiological and/or PCR COVID-19 positive

Exclusion Criteria:

* Patients or professionals who do not sign informed consent

Primary outcomes:
measure: IgG anti-COVID-19
timeFrame: From May to July
measure: IgM anti-COVID-19
timeFrame: From May to July
measure: IgA anti-COVID-19
timeFrame: From May to July
Secondary outcomes:
measure: Time of onset symptoms
timeFrame: From May to July
measure: COVID-19 PCR results
timeFrame: From May to July
measure: Radiological studies
timeFrame: From May to July
Other outcomes:
Locations:
city: Sabadell
country: Spain
facility: Parc Tauli University Hospital
state: Barcelona
Study officials:
References:
Clinical trial NCT03450837: Impaired HDL and Coronary Artery Disease in Anabolic Androgenic Steroid Users
Official title: Diminished Macrophage Cholesterol Efflux Mediated by HDL and Coronary Artery Disease in Young Male Anabolic Androgenic Steroid Users
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: Coronary artery disease; HDL; anabolic steroids
Lead sponsor: University of Sao Paulo General Hospital
Sponsor class: OTHER
Collaborators: name: Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted: 2018-03-01
Enrollment: 51
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Anabolic androgenic steroids users and nonusers were recreational weightlifters or amateur bodybuilding athletes who were recruited from gymnasiums.

Sedentary control group was recruited from community sample.

Brief summary: Anabolic androgenic steroids (AASs) have been associated with coronary artery disease (CAD). The illicit use of these substances also leads to a remarkable decrease in high-density lipoprotein (HDL) plasma concentration, which could be a key factor in the atherosclerotic process. The investigators tested the functionality of HDL by cholesterol efflux and antioxidant capacity and its association with CAD in young men.

Detailed description: Twenty strength-trained AAS users (AASU) age 29±5 yr, 20 age-matched strength-trained AAS nonusers (AASNU), and 10 sedentary controls (SC) were enrolled.

HDL concentration and functionality by measuring the 14C-cholesterol efflux mediated by HDL and the ability of HDL in inhibiting LDL oxidation were evaluated.

Coronary artery was evaluated with coronary computed tomography angiography.

Eligibility criteria: Inclusion Criteria:

* Anabolic androgenic steroids users and Anabolic androgenic steroids nonusers groups had been involved in strength training for at least 2 years;
* Anabolic androgenic steroids users should be self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year;
* All anabolic androgenic steroids users were on a cycle over the course of the study;
* Sedentary control group: sedentary men without cardiovascular disease.

Exclusion Criteria:

* Smoking;
* Alcohol consumption;
* Use of diuretics and/or antihypertensive medications;
* Liver and kidney disease

Primary outcomes:
measure: Concentration and the functionality of HDL
timeFrame: 1 day
Secondary outcomes:
measure: Prevalence of CAD in young men anabolic steroids users
timeFrame: 1 day
Other outcomes:
Locations:
Study officials:
affiliation: Heart Institute
name: Maria Janieire NN Alves, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03190837: A Long-term Follow-up Study of Gaucher Disease
Official title: A Long-term Follow-up Study of Gaucher Disease
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Gaucher Disease
Keywords: gaucher
gaucher disease
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2017-06-19
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We will be recruiting patients with Gaucher Disease of all ages, followed at Duke University Medical Center, or non-Duke patients who have contacted Duke and expressed interest in participating.

Brief summary: The study aims are to: a) identify the long-term natural history of Gaucher disease, b) evaluate long-term treatment efficacy of enzyme replacement therapy (ERT) and substrate reduction therapy (SRT), and c) identify potential long-term complications of this disorder. These aims will be accomplished through long-term record review of individuals with all three types of Gaucher disease.

Detailed description: The study aims (aims a-c) will be accomplished by the systematic monitoring of health records. Health information will be extracted from medical records for patients followed at Duke. Medical records will be requested from treating physicians outside of Duke. The PI, (Dr. Kishnani) a recognized expert in Gaucher disease, is a consultant to the treating physician of virtually all subjects in this study. Subject health status will be monitored at least on an annual basis and as regularly as the medical information is obtained from the treating physician. Enrollment in this study will not alter the standard of care treatment for patients with Gaucher disease.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Gaucher Disease

Exclusion Criteria:

* Not meeting Inclusion criteria

Primary outcomes:
measure: Document effects of Gaucher disease in different systems of body, including nervous system, liver, and spleen.
timeFrame: 10 years
Secondary outcomes:
measure: Document adverse events subjects experience on enzyme replacement therapy
timeFrame: 10 years
measure: Document adverse events of subjects on substrate reduction therapy
timeFrame: 10 years
measure: Document long-term complications in Gaucher Disease.
timeFrame: 10 years
measure: Change in 36-Item Short Form Survey (SF-36) collected every 6 months/1 year.
timeFrame: 10 years
measure: Change in Small Fiber Neuropathy Screening List (SFNSL) collected every 6 months/1 year.
timeFrame: 10 years
measure: Document number of subjects experiencing neurological symptoms related to Gaucher, by using Neurological Follow-up exam
timeFrame: 10 years
measure: Change in Parkinson's checklist collected every 6 months/1 year.
timeFrame: 10 years
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Duke University
name: Priya Kishnani, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06115837: Prognosis Stratification for pT4bN0M0 Colorectal Cancer Following Multivisceral Resection
Official title: Prognosis Stratification for pT4bN0M0 Colorectal Cancer Following Multivisceral Resection: A Multi-institutional Retrospective Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colorectal Cancer
Keywords: Colorectal Cancer
Multivisceral resection
Prognosis
Lead sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sponsor class: OTHER
First posted: 2023-11-03
Enrollment: 172
Sex: ALL
Minimum age (years): 18
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The patient experienced multivisceral resection for pT4bN0M0 colorectal cancer from January 2010 to December 2021.

Brief summary: The purpose of this study was to identify the prognostic factors of affecting pT4bN0M0 colorectal cancer patients, so as to better stratify the prognostic differences among patients with the same stage.

Detailed description: Patients with pT4b stage colorectal cancer (CRC) are a complex and special group due to the diversity of infiltrated organs, patients with the same stage often have different prognosis after multivisceral resection (MVR), some important prognostic factors have not been deeply explored, and additional prognostic factors are needed to improve the survival assessment of these patients. In this study, investigators attempted to evaluate the prognostic factors of pT4bN0M0 colorectal cancer, and then stratify the prognosis of such patients to distinguish the survival differences among different patients.

This study was a multicenter retrospective cohort study based on a multicenter database which contained hospitalization.The prognostic factors of pT4bN0M0 colorectal cancer patients were analyzed, and the prognostic grading system was constructed to accurately stratify the survival of pT4bN0M0 patients.

Eligibility criteria: Inclusion Criteria:

1. The patient was pathologically diagnosed as colorectal adenocarcinoma.
2. Patients with pT4bN0M0 colorectal cancer.
3. Patients with R0 resection.

Exclusion Criteria:

1. Patients with distant metastasis.
2. Patients with R1 or R2 resection.
3. Patients with lymph node metastasis
4. Recurrent colorectal cancer.

Primary outcomes:
measure: Overall survival
timeFrame: The endpoint of the overall survival assessment is the last follow-up or patient death. Follow-up time is up to 72 months.
measure: Cancer specific survival
timeFrame: The endpoint of the cancer specific survival assessment is the patient death due to cancer. Follow-up time is up to 72 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Cancer Hospital Chinese Academy of Medical Sciences
Study officials:
References:
Clinical trial NCT01142037: Development of a Biomarker for Dietary Furanocoumarins
Official title: Development of a Biomarker for Dietary Furanocoumarins
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer
Healthy
Keywords: Healthy volunteer
Lead sponsor: University of Minnesota
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2010-06-11
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Certain plant foods are high in furanocoumarins. Test tube and animal studies suggest that furanocoumarins may help prevent cancer. It is difficult to determine in humans if furanocoumarins do prevent cancer because there isn't an objective way to tell who has eaten these compounds. This study will develop a urine test to determine if an individual ate foods that contain furanocoumarins.


Eligibility criteria: Inclusion Criteria:

* Must be at least 18 years of age
* Healthy

Exclusion Criteria:

* History of gastrointestinal, hepatic or renal disorder
* Currently taking any prescription or over-the-counter medication
* Currently taking any herbal supplement
* Pregnant or lactating
* Allergies to foods that will be used (parsnips and parsley)

Primary outcomes:
measure: Urinary Biomarker Results for Dietary Furanocoumarins
timeFrame: Week 1
Secondary outcomes:
measure: Mean Concentration of Dietary Furanocoumarin in Urine
timeFrame: Week 1, 2 and 3
Other outcomes:
Locations:
city: St. Paul
country: United States
facility: Department of Food Science and Nutrition, University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Sabrina Peterson, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04251637: Non Invasive Cardiac Output Evaluation With Starling SV for Lung Elective Surgery
Official title: Non Invasive Cardiac Output Evaluation With Starling SV for Lung Elective Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thoracic
Surgery
Keywords: esophageal Doppler
thoracic surgery
pulmonary exeresis
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2020-02-05
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: - Adult patients scheduled in Louis Pradel hospital operating theater (Lyon University Hospital) for elective Lung surgery (lobectomy, bilobectomy or pneumonectomy); by thoracotomy and / or thoracoscopy.

Brief summary: Intraoperative hemodynamic optimization decreases postoperative complications and length of stay in high risk patient. Therefore, continuous monitoring of cardiac output (Qc) is recommended to guide fluid management. Thoracic bio-reactance is a recent technique that allows cardiac output non-invasive monitoring. However, additional clinical validation studies in humans are required to better define the typologies of patients for whom this monitoring could be proposed routinely. Lung surgery is defined as an intermediate or high risk surgery regarding postoperative cardiac complications. However, surgical patients rarely benefit from continuous monitoring of cardiac output, the available methods being considered too invasive or insufficiently reliable in daily practice. Thoracic bio-reactance (Non Invasive Cardiac Output Monitor (NICOM) Starling SV) has not been studied in this subgroup of clinically relevant patients.


Eligibility criteria: Inclusion Criteria:

* Adult patients
* Scheduled in Louis Pradel hospital operating theater (Lyon University Hospital) for elective Lung surgery (lobectomy, bilobectomy or pneumonectomy); by thoracotomy and / or thoracoscopy.
* Having stated their non opposition to be part of this protocol

Exclusion Criteria:

* Pregnant women ;
* unemancipated minors;
* Persons unable to express their consent;
* Patients with contraindications to the placement of an oesophageal Doppler probe
* Patients with suspicion of pathology or oesogastric lesion (dysphagia, diverticulum, stenosis ...)
* Patients known for stage 2 or higher oesophageal varices
* Patients with a history of significant mediastinal irradiation, or bariatric surgery.
* Patients who have been treated in a therapeutic trial within 30 days of enrollment or who wish to participate in an ongoing study that may interfere with this study.
* Persons benefiting from legal protection measures;
* Patients unable to understand study objectives or refusing to comply with postoperative instructions

Primary outcomes:
measure: cardia output measurement
timeFrame: Day 0
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hôpital Louis Pradel
Study officials:
References:
Clinical trial NCT03314337: Pancreatic Stent for Distal Pancreatectomy
Official title: A Prospective Randomized Controlled Study Comparing Outcomes of Distal Pancreatectomy With or Without Pancreatic Stent
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Distal Pancreatectomy
Keywords: Distal Pancreatectomy
Pancreatic stent
Post-operative pancreatic fistula
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2017-10-19
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to compare outcomes of patients undergoing distal pancreatectomy with or without pancreatic stent


Eligibility criteria: Inclusion Criteria:

1. Patients undergoing distal pancreatectomy
2. Signed the informed consents

Exclusion Criteria:

1. Recurrence patients
2. pre-operative anti-cancer treatment
3. patients with contraindication(hepatic/ respiratory/ renal dysfunction, etc )
4. AJCC stage IV
5. pre operative oddi'ssphincter incision
6. operation non radical
7. pancreatic stent not at place

Primary outcomes:
measure: all-cause mortality / complications
timeFrame: Hospitalization 30days（duration of hospital stay)
Secondary outcomes:
measure: all-cause mortality / complications
timeFrame: 30 days after operation
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Ruijin Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT06966037: Uric Acid Levels and Migraine in Children
Official title: Evaluation of Uric Acid Levels in Pediatric Patients With Migraine
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Migraine in Children
Keywords: migraine
children
uric acid levels
Lead sponsor: Mersin University
Sponsor class: OTHER
First posted: 2025-05-11
Enrollment: 2
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients diagnosed with migraine were included as the study group, while the control group consisted of patients who presented to the pediatric neurology clinic during the same period for neuromotor development follow-up examinations.

Brief summary: Migraine is recognized as one of the most prevalent neurological disorders. The exact pathophysiological mechanisms underlying migraine have not yet been fully elucidated. The present study aims to compare serum uric acid levels between pediatric patients with migraine and a control group. Additionally, this study seeks to explore the potential relationship between migraine attack frequency and gender differences in pediatric patients

Detailed description: Migraine is recognized as one of the most prevalent neurological disorders. The exact pathophysiological mechanisms underlying migraine have not yet been fully elucidated. The present study aims to compare serum uric acid levels between pediatric patients with migraine and a control group. Additionally, this study seeks to explore the potential relationship between migraine attack frequency and gender differences in pediatric patients Patients diagnosed with migraine were included as the study group, while the control group consisted of patients who presented to the pediatric neurology clinic during the same period for neuromotor development follow-up examinations.

Migraine patients are influenced by multiple factors, including dietary habits, levels of physical activity, and various psychosocial determinants.

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with migraine

Exclusion Criteria:

Cerebral palsy Non-migraine headache Epilepsy Multiple congenital anomalies Congenital metabolic diseases Control group

Inclusion Criteria:

Healthy children Exclusion Criteria Neuromotor developmental delay Multiple congenital anomalies Non-migraine headache Epilepsy

Primary outcomes:
measure: Evaluation of Uric Acid Levels in Pediatric Patients with Migraine
timeFrame: 01.08.2019 and 01.03.2024
Secondary outcomes:
Other outcomes:
Locations:
city: Mersin
country: Turkey
facility: Mersin University
Study officials:
References:
Clinical trial NCT01945437: Magnesium and TKA Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pain
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2013-09-18
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The hypothesis of this study is that in staged bilateral total knee arthroplasty (TKA, magnesium sulfate administered during the perioperative period of the first TKA may decrease pain after the second TKA. It is known that pain is greater in the second TKA than in the first. Therefore, we compared pain of the second TKA between the magnesium and control groups.


Eligibility criteria: Inclusion Criteria: American society of anesthesiologist physical status 1 - 2. patients scheduled to undergo staged bilateral TKA

Exclusion Criteria: American society of anesthesiologist physical status \>3

-

Primary outcomes:
measure: Pain
timeFrame: from the end of the TKA until 48 hour
Secondary outcomes:
measure: analgesic
timeFrame: from the end of the TKA until 48 hours
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04546737: Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
Official title: Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Covid19
Neurological Manifestations
Brain Damage
Keywords: Covid19
Neurological Manifestations
MRI and NMR spectroscopy
Radiological semiology
Spectral profile
Brain Damage
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2020-09-14
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Viral pandemics, such as HIV and SARS-Cov-V1, have shown that they can lead to acute and / or delayed neurological complications. At the actual context of the pandemic Coronavirus disease 2019 (COVID-19), neurological manifestations seem to be confirmed since in 85% of COVID-19 patients, present neurological symptoms, including anosmia, ageusia, periorbital pain, dizziness, fatigue, even moderate headache, moderate memory and/or behavioral disorders.

However, these neurological manifestations are not well studied and their radiological features are not well described. It is therefore important to assess these potential neurological complications in COVID-19 patients. To the investigator knowledge, there is no previous study in the literature describing spectral brain changes in COVID + patients. Thus, the goal of this work is to describe the radiological semiology using MRI and particularly Magnetic Resonance Spectroscopic (MRS) biomarkers in the evaluation of acute and / or delayed brain damage in COVID + patients presenting a neurological manifestations that are initially related to the cranial nerves damage.


Eligibility criteria: Inclusion Criteria:

* Major COVID-19 patient (≥18 years old)
* COVID-19 patient presenting at least one the neurological manifestations:

anosmia, ageusia, periorbital pain, dizziness, fatigue, moderate headache, moderate memory and behavioral disorders.

* Patient who have signed an informed consent form for the study

Exclusion Criteria:

* Patient under guardianship or curators or under judicial protection
* Pregnant and breastfeeding women

Primary outcomes:
measure: Variation from baseline of MRI radiological semiology in COVID-19 patients
timeFrame: 9 months after patient inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens
Study officials:
References: